Abstract 885P
Background
This study aimed to investigate the feasibility of using ligand-targeted polymerase chain reaction (LT-PCR) to detect folate receptor-positive circulating tumor cells (FR+CTCs) and their potential role as an auxiliary marker for diagnosis and treatment monitoring in nasopharyngeal carcinoma (NPC).
Methods
This was a single-center, prospective, non-interventional clinical study at Fujian Cancer Hospital. The study included newly diagnosed nasopharyngeal carcinoma patients with at least one measurable lesion and a benign control group. Patients underwent comprehensive treatment based on radical radiotherapy, and the level of FR+CTC was dynamically detected after treatment. FR+CTC was quantitated using ligand-targeted PCR and verified using immunofluorescence. The ROC curve was used to determine specificity and sensitivity thresholds, and the AUC was calculated. Comparisons between groups were performed using statistical tests, and p < 0.05 was considered statistically significant.
Results
A total of 254 subjects were included in the study, including 145 newly diagnosed NPC patients and 109 healthy volunteers. The study found that the level of FR+CTC was significantly higher in NPC patients than in healthy individuals, and the levels were also higher in stage III and IV patients. The FR+CTC detection method had a higher AUC, and the cut-off value between the NPC and control groups was 9.380 FU/3ml, with a sensitivity of 99.1% and a specificity of 79.2%. The study also found that FR+CTC levels were associated with gender, age, TNM stage, and MPTD, but not with the level of EB-DNA. After radiotherapy, most patients showed a significant decrease in FR+CTC levels, indicating the potential of FR+CTC as a dynamic biomarker for monitoring treatment response in NPC.
Conclusions
This study demonstrates that LT-PCR technology can accurately detect FR+CTCs in NPC patients. FR+CTC has the potential to be used not only as an auxiliary biomarker for early detection and diagnosis of nasopharyngeal carcinoma, but also as a potential marker for dynamic assessment and monitoring of disease progression, recurrence, and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12